Improved IBDQ at week 52 · people with active UC
Adalimumab probably leads to higher improved IBDQ at week 52 compared with placebo (moderate certainty).
1 finding from 1 review
Change in DLQI score (LOCF) · participants with hidradenitis suppurativa
2 findings from 1 review
Frequency of serious adverse effects · participants with hidradenitis suppurativa
Adalimumab weekly showed no clear difference in frequency of serious adverse effects compared with placebo (moderate certainty).
1 finding from 1 review
Treatment discontinuation · participants with hidradenitis suppurativa
Adalimumab weekly showed no clear difference in frequency of treatment discontinuation compared with placebo (moderate certainty).
1 finding from 1 review
Proportion of participants with infectious adverse effects · participants with hidradenitis suppurativa
Adalimumab weekly showed no clear difference in proportion of participants with infectious adverse effects compared with placebo (moderate certainty).
1 finding from 1 review
Proportion with improvement in pain VAS · participants with hidradenitis suppurativa
Adalimumab weekly probably leads to higher proportion with improvement in pain VAS compared with placebo (moderate certainty).
1 finding from 1 review
Change in modified Sartorius scale score (imputation) · participants with hidradenitis suppurativa
1 finding from 1 review
Treatment discontinuation · participants with hidradenitis suppurativa
Adalimumab every other week showed no clear difference in frequency of treatment discontinuation compared with placebo (high certainty).
1 finding from 1 review
Proportion of participants with infectious adverse effects · participants with hidradenitis suppurativa
Adalimumab every other week showed no clear difference in proportion of participants with infectious adverse effects compared with placebo (high certainty).
1 finding from 1 review
Change in Pain VAS · participants with hidradenitis suppurativa
1 finding from 1 review
Proportion with improvement in pain · participants with hidradenitis suppurativa
Adalimumab every other week showed no clear difference in proportion with improvement in pain compared with placebo (moderate certainty).
1 finding from 1 review
Change in Sartorius scale score (LOCF) · participants with hidradenitis suppurativa
1 finding from 1 review
Change in DLQI score (LOCF) · participants with hidradenitis suppurativa
1 finding from 1 review
Frequency of serious adverse effects · participants with hidradenitis suppurativa
Adalimumab every other week showed no clear difference in frequency of serious adverse effects compared with placebo (high certainty).
1 finding from 1 review
Adalimumab · people with chronic plaque psoriasis
Any systemic treatment showed no clear difference in adalimumab compared with placebo (moderate certainty).
2 findings from 1 review
Intervention not reported
Adalimumab (3 RCTs; 37 participants) · surgically induced remission in Crohn's disease
The intervention may leads to lower adalimumab (3 RCTs; 37 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Adalimumab (1 RCT; 16 participants) · surgically induced remission in Crohn's disease
It is very uncertain whether the intervention changes adalimumab (1 RCT; 16 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Adalimumab (2 RCTs; 26 participants) · surgically induced remission in Crohn's disease
The intervention may leads to lower adalimumab (2 RCTs; 26 participants) (low certainty).
1 finding from 1 review
Clinical relapse · patients with Crohn's disease (active disease population with clinical response at baseline)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Loss of clinical response (at 22 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether infliximab changes loss of clinical response (at 56 weeks, less than 100 points in CDAI… compared with adalimumab (very low certainty).
1 finding from 1 review